Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy.
Animals
Carcinogenesis
/ genetics
Cell Proliferation
/ genetics
Cell Transformation, Neoplastic
/ genetics
Disease Models, Animal
Glycolysis
/ genetics
Humans
Mesenchymal Stem Cells
/ metabolism
Metabolome
/ genetics
Mice
Mitochondria
/ genetics
Mutant Proteins
/ genetics
Neoplasms
/ genetics
Tumor Suppressor Protein p53
/ genetics
Journal
Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
07
06
2018
accepted:
08
10
2018
revised:
28
09
2018
pubmed:
11
11
2018
medline:
1
9
2020
entrez:
11
11
2018
Statut:
ppublish
Résumé
It is well accepted that malignant transformation is associated with unique metabolism. Malignant transformation involves a variety of cellular pathways that are associated with initiation and progression of the malignant process that remain to be deciphered still. Here we used a mouse model of mutant p53 that presents a stepwise progressive transformation of adult Mesenchymal Stem Cells (MSCs). While the established parental p53Mut-MSCs induce tumors, the parental p53WT-MSCs that were established in parallel, did not. Furthermore, tumor lines derived from the parental p53Mut-MSCs (p53Mut-MSC-TLs), exhibited yet a more aggressive transformed phenotype, suggesting exacerbation in tumorigenesis. Metabolic tracing of these various cell types, indicated that while malignant transformation is echoed by a direct augmentation in glycolysis, the more aggressive p53Mut-MSC-TLs demonstrate increased mitochondrial oxidation that correlates with morphological changes in mitochondria mass and function. Finally, we show that these changes are p53Mut-dependent. Computational transcriptional analysis identified a mitochondrial gene signature specifically downregulated upon knock/out of p53Mut in MSC-TLs. Our results suggest that stem cells exhibiting different state of malignancy are also associated with a different quantitative and qualitative metabolic profile in a p53Mut-dependent manner. This may provide important insights for cancer prognosis and the use of specific metabolic inhibitors in a personalized designed cancer therapy.
Identifiants
pubmed: 30413783
doi: 10.1038/s41418-018-0227-z
pii: 10.1038/s41418-018-0227-z
pmc: PMC6748146
doi:
Substances chimiques
Mutant Proteins
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1566-1581Références
Am J Hum Genet. 2000 Nov;67(5):1104-9
pubmed: 11013136
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Genet Med. 2004 Mar-Apr;6(2):73-80
pubmed: 15017329
Nat Rev Cancer. 2005 Apr;5(4):275-84
pubmed: 15803154
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Immunol Methods. 2006 Apr 20;311(1-2):117-29
pubmed: 16563425
Science. 2006 Jun 16;312(5780):1650-3
pubmed: 16728594
Cell. 2006 Jul 14;126(1):107-20
pubmed: 16839880
Nature. 2008 Apr 3;452(7187):650-3
pubmed: 18385740
Cancer Res. 1991 Nov 15;51(22):6094-7
pubmed: 1933872
Nat Rev Cancer. 2009 Oct;9(10):701-13
pubmed: 19693097
Nat Rev Cancer. 2009 Oct;9(10):691-700
pubmed: 19759539
Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7455-60
pubmed: 20378837
J Exp Med. 2010 Sep 27;207(10):2127-40
pubmed: 20696700
Science. 2010 Dec 3;330(6009):1340-4
pubmed: 21127244
Nature. 2011 Jan 20;469(7330):314-22
pubmed: 21248838
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Stem Cell Rev Rep. 2011 Sep;7(3):560-8
pubmed: 21437576
FEBS J. 2011 Nov;278(22):4243-51
pubmed: 21929724
Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16259-64
pubmed: 21930938
Cell. 2012 Jan 20;148(1-2):244-58
pubmed: 22265415
Biochim Biophys Acta. 2012 Sep;1823(9):1604-16
pubmed: 22554985
J Physiol. 2012 Jul 15;590(14):3349-60
pubmed: 22586215
Genes Dev. 2012 Sep 1;26(17):1926-44
pubmed: 22899010
Antioxid Redox Signal. 2013 Aug 1;19(4):331-43
pubmed: 23320803
Cell Stem Cell. 2013 Mar 7;12(3):329-41
pubmed: 23333149
N Engl J Med. 2013 Mar 14;368(11):1027-32
pubmed: 23484829
Neurology. 2013 Apr 23;80(17):1577-83
pubmed: 23553477
Nat Commun. 2013;4:2935
pubmed: 24343302
Mol Cancer Res. 2014 Jan;12(1):3-13
pubmed: 24442106
Nat Cell Biol. 2014 Apr;16(4):357-66
pubmed: 24658687
Cell Death Differ. 2014 Sep;21(9):1419-31
pubmed: 24832469
Nature. 2014 Oct 30;514(7524):628-32
pubmed: 25119024
Methods Mol Biol. 2015;1241:23-38
pubmed: 25308485
Sci Rep. 2015 Jul 15;5:12410
pubmed: 26174737
Cell Metab. 2015 Oct 6;22(4):590-605
pubmed: 26365176
Cancer Cell. 2015 Dec 14;28(6):815-829
pubmed: 26678341
Curr Opin Genet Dev. 2016 Jun;38:16-22
pubmed: 27003724
Exp Hematol. 2016 Sep;44(9):866-873.e4
pubmed: 27118043
Br J Cancer. 2016 Jun 14;114(12):1305-12
pubmed: 27219018
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):null
pubmed: 27235476
Cell Metab. 2016 Jul 12;24(1):104-17
pubmed: 27411012
Cell. 2016 Jul 28;166(3):555-566
pubmed: 27471965
Nature. 2017 Jan 12;541(7636):222-227
pubmed: 27798600
J Clin Invest. 2017 Jan 3;127(1):132-136
pubmed: 27869650
Cold Spring Harb Protoc. 2016 Dec 1;2016(12):
pubmed: 27934682
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Mol Cell Biol. 2017 Nov 28;37(24):
pubmed: 28993478
Oxid Med Cell Longev. 2017;2017:5047168
pubmed: 29018510
Cancer Res. 2018 Oct 15;78(20):5833-5847
pubmed: 30154152
Blood. 1988 Aug;72(2):567-72
pubmed: 3165295
Proc Natl Acad Sci U S A. 1984 Mar;81(5):1371-4
pubmed: 6143319
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
J Exp Med. 1996 Apr 1;183(4):1797-806
pubmed: 8666936
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098